Amylin Sues Eli Lilly Over Diabetes Drug Development Deal

INDIANAPOLIS - (AP) Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product. Amylin, which is based in San Diego, said. . . . Full version available to subscribers.